Answers are grounded in this paper and cite their sources.
Reviews approaches for screening dyslipidaemia and tailoring lipid-lowering therapy, highlighting methods to improve primary and secondary cardiovascular outcomes.
Dyslipidaemia is a key risk factor for cardiovascular disease, and its identification and treatment is important for both primary and secondary prevention. This article discusses how to screen for dyslipidaemia and optimise lipid‐lowering therapy to improve cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Viljoen et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: